Therapy Areas

INFECTIOUS DISEASE

We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and unknown infectious diseases. We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way. Allowing us to be at the forefront of patient response when it comes to infectious disease threats, affecting millions of people every year. We currently have five prophylactic vaccines in our development pipeline.

 

Meningitis ACYW135 Conjugate

IVIV 304

  • Platform

    Conjugation

  • Market

    The meningococcal vaccine market is diverse and complex with regional variations in serogroup distribution and significant use outside of routine immunization. The global supply of conjugate MenACWY is insufficient to meet demand growth triggered by rising incidence of serogroups C and W and the limited availability of polysaccharide vaccines. Low and middle income countries struggle for access to multivalent and conjugate vaccines due to limited global supply and high cost for conjugate vaccines. With this in consideration, our NMCV-4 program continues to be in development through self-funding.

Pentavalent Vaccine (DTaP-IPV-Hib)
IVIV 521

  • Platform

    Conjugation

  • Market

    The meningococcal vaccine market is diverse and complex with regional variations in serogroup distribution and significant use outside of routine immunization. The global supply of conjugate MenACWY is insufficient to meet demand growth triggered by rising incidence of serogroups C and W and the limited availability of polysaccharide vaccines. Low and middle income countries struggle for access to multivalent and conjugate vaccines due to limited global supply and high cost for conjugate vaccines. With this in consideration, our NMCV-4 program continues to be in development through self-funding.

  • Disease Protection

    Pentavalent vaccine protects against five major diseases

    1. Diphtheria
    2. Tetanus
    3. Pertussis (Whooping Cough)
    4. Haemophilus Influenza Type B
    5. Polio

Hexavalent Vaccine (DTaP-IPV-Hib-HepB)
IVIV 859

  • Platform

    Conjugation

  • Market

    InventVacc is committed to supporting low-income countries with expectations of a higher quality of life

  • Disease Protection

    Hexavalent vaccine protects against five major diseases

    1. Diphtheria
    2. Tetanus
    3. Pertussis (Whooping Cough)
    4. Haemophilus Influenza Type B
    5. Polio
    6. Hepatitis B

mRNA Vaccine
IVIV 391

  • Confidential

    Confidential Information

mRNA Vaccine
IVIV 399

  • Confidential

    Confidential Information

Multivalent pneumococcal vaccine –
PCV 25 Adult (Licensed product)

IVIV 433

  • Platform

    Conjugation

  • Market

    The value of the pneumococcal vaccines market will steadily grow over from USD 7.2 billion (2019) to over USD 11 billion by 2030 representing the second largest segment of the vaccine industry (measured by dollar volume).

IMMUNOTHERAPY

We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and future types of  cancers. We are committed to building on our established  licensed Conjugation technology platform in addition to introducing new innovations to the novel  licensed mRNA technology to utilize it in the most reliable way. Allowing us to be at the forefront of patient response when it comes to cancer treatments, affecting millions of people every year.


HPV (high valency) Vaccine

IVIV 820

  • Platform

    Conjugation

  • Market

    Human papillomavirus infection (HPV infection) is an infection caused by human papillomavirus (HPV), a DNA virus from the Papillomaviridae family, Many HPV infections cause no symptoms, and 90% resolve within two years, however in some cases, an HPV infection persists and results in either warts or precancerous lesions. These lesions, depending on the site affected, increase the risk of cancer of the cervix, vulva, vagina, penis, anus, mouth, tonsils, or throat. Nearly all cervical cancer are due to HPV; two strains, HPV16 and HPV18, account for 70% of cases. HPV16 is responsible for almost 90% of HPV positive, oropharyngeal cancers. Between 60% and 90% of the other cancers listed above are also linked to HPV. HPV is the most common sexually transmitted infection (STI) globally. Worldwide an estimated 569,000 new cases of cervical cancer occur annually , with 311,000 deaths. Around 85% of these cervical cancers occurred in low and middle-income countries. In the United States, about 30,700 cases of cancer due to HPV occur each year.

RARE DISEASE

We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and yet to be discovered rare diseases. There are currently more than 4,000 life threatening rare diseases with no treatment, 400 million people worldwide are currently suffering from rare diseases without reliable treatment or prophylaxis.  We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way allowing us to be at the forefront of patient response when it comes to rare diseases threats, affecting millions of people every year.


Haemophilus Influenza Type A Vaccine (Hia)

IVIV 378

  • Platform

    Conjugation

  • Market

    Hemophilus Influenza A was recognized as an important pathogen causing severe infections in young children. Remarkably, the highest incidence rates of invasive Hia disease are found in North American Indigenous populations, specifically Indigenous tribes of Navajo and Inuit. In these populations Hia has become the leading cause of bacterial meningitis among children.

  • INFECTIOUS DISEASES

    We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and unknown infectious diseases. We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way. Allowing us to be at the forefront of patient response when it comes to infectious disease threats, affecting millions of people every year. We currently have five prophylactic vaccines in our development pipeline 

    See Vaccines
    INFECTIOUS DISEASES
  • IMMUNOTHERAPHY

    We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and future types of  cancers. We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way. Allowing us to be at the forefront of patient response when it comes to cancer treatements, affecting millions of people every year. 

    See Vaccines
    IMMUNOTHERAPHY
  • RARE DISEASES

    We believe the world needs a mix of traditional and innovative approaches in the prevention of both known and yet to be discovered rare diseases. There are currently more than 4,000 life threatening rare diseases with no treatment, 400 million people worldwide are currently suffering from rare diseases without reliable treatment or prophylaxis.  We are committed to building on our established licensed Conjugation technology platform in addition to introducing new innovations to the novel licensed mRNA technology to utilize it in the most reliable way allowing us to be at the forefront of patient response when it comes to rare diseases threats, affecting millions of people every year. 

    See Vaccines
    RARE DISEASES

PIPELINE

Platform: Conjugation

Rights: Worldwide

VACCINE

DISCOVERY

PRE-CLINICAL

PHASE 1

PHASE 2

PHASE 3

Men ACYW135 : IVIV 304
Pentavalent (DTaP-IPV-Hib) : IVIV 521
Hexavalent (DTaP-IPV-Hib – HepB) : IVIV 859
Haemophilus Influenza Type A (Hia) : IVIV 378
HPV (High Valency) : IVIV 820

Men ACYW135 Conjugate Vaccine

ID: IVIV 304

Platform: Conjugation

Stage: Pre-clinical

Rights: Worldwide

Pre-Clinical

Pentavalent (DTaP-IPV-Hib)

ID: IVIV 521

Platform: Conjugation

Stage: Discovery

Rights: Worldwide

Discovery

Hexavalent (DTaP-IPV-Hib – HepB)

ID: IVIV 859

Platform: Conjugation

Stage: Discovery

Rights: Worldwide

Discovery

Haemophilus Influenza Type A Vaccine (Hia)

ID: IVIV 378

Platform: Conjugation

Stage: Phase 1

Rights: Worldwide

Phase 1

HPV (High Valency)

ID: IVIV 820

Platform: Conjugation

Stage: Discovery

Rights: Worldwide

Discovery

Adult Vaccines

Platform: mRNA

Rights: Worldwide

VACCINE

DISCOVERY

PRE-CLINICAL

PHASE 1

PHASE 2

PHASE 3

mRNA Airborne Infectious Disease Vaccine : IVIV 391
mRNA Airborne Infectious Disease Vaccine : IVIV 399

Platform: Conjugation

Rights: Confidential

VACCINE

DISCOVERY

PRE-CLINICAL

PHASE 1

PHASE 2

PHASE 3

PCV-25 Adult (Licensed Product): IVIV 43

mRNA Airborne Infectious Disease Vaccine

ID: IVIV 391

Platform: mRNA

Stage: Discovery

Rights: Worldwide

Discovery

mRNA Airborne Infectious Disease Vaccine

ID: IVIV 399

Platform: mRNA

Stage: Discovery

Rights: Worldwide

Discovery

PCV-25 Adult (Licensed Product):

ID: IVIV 433

Platform: Conjugation

Stage: Phase 1

Rights: Confidential

Phase 1

TECHNOLOGY PLATFORMS

CONJUGATION

Our licensed conjugation technology is designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines. Our licensed technology addresses the reduction in immunogenicity observed with other vaccines by increasing the availability of antigenic epitopes. In addition, our licensed proprietary technology increases the carrier function, and suppresses the immune response towards carriers.


OUR PROCESS

Target preparation - Capsular Polysaccharide reduction

Carrier preparation - Carrier protein activation, followed by proprietary linker attachment

Conjugation - Functionalizing the activated Polysaccharide with a linker

Conjugation complete - Maximizing long term storage stability by means of a buffer

 

mRNA

Vaccine design with better LNP for delivery of mRNA to the cells.


More information coming soon.

 

  • CONJUGATION

    Our licensed conjugation technology is designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines. Our licensed technology addresses the reduction in immunogenicity observed with other vaccines by increasing the availability of antigenic epitopes. In addition, our licensed proprietary technology increases the carrier function, and suppresses the immune response towards carriers.


    OUR PROCESS

    Target preparation - Capsular Polysaccharide reduction

    Carrier preparation - Carrier protein activation, followed by proprietary linker attachment

    Conjugation - Functionalizing the activated Polysaccharide with a linker

    Conjugation complete - Maximizing long term storage stability by means of a buffer

    CONJUGATION
  • mRNA

    Vaccine design with better LNP for delivery of mRNA to the cells.


    More information coming soon.

    mRNA